1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?

 
• By Alexandra Shimmings

Scrip talked to Johnson & Johnson’s vice president of oncology global medical affairs, Mark Wildgust, about how the healthcare giant hopes to plant a flag on Tagrisso’s mountain with its trio of Phase III butterfly-themed studies for the bispecific antibody Rybrevant presented at ESMO.    

Butterfly
• Source: Shutterstock

When the late-breaking abstracts from the European Society for Medical Oncology meeting in Madrid were released early last week, one of the more eagerly pored-over readouts was for Johnson & Johnson’s MARIPOSA study of its bispecific antibody product targeting EGFR and MET, Rybrevant, in non-small cell lung cancer (NSCLC).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D